PAD plus lenalidomide in multiple myeloma - a promising four-drug regimen in newly diagnosed and advanced disease

被引：0
|
作者：
Schreder, M. [1 ]
Danhof, S. [1 ]
Rasche, L. [1 ]
Strifler, S. [1 ]
Einsele, H. [1 ]
Knop, S. [1 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P870
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [21] A Better Mobilization Regimen for Newly Diagnosed Multiple Myeloma Patients
    Abuabdou, Ahmed Y.
    Rosenbaum, Eric R.
    Usmani, Saad
    Barlogie, Bart
    Cottler-Fox, Michele
    BLOOD, 2011, 118 (21) : 1730 - 1730
  • [22] Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma
    Rabindra Kumar Jena
    Trupti Rekha Swain
    Sandeep Sadashivrao Kansurkar
    Manorama Swain
    European Journal of Clinical Pharmacology, 2012, 68 : 881 - 884
  • [23] Immunological Consequences of Lenalidomide with and without Dexamethasone in Newly Diagnosed Multiple Myeloma
    Kloeber, Jake A.
    Kimlinger, Teresa K.
    Haug, Jessica L.
    Henderson, Kimberly J.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD, 2019, 134
  • [24] Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
    Yin, Junjing
    Zhou, Xia
    Li, Xuemei
    Yuan, Chenglu
    Chu, Xiaoxia
    Hao, Lumei
    Wu, Hongying
    Zhong, Yuping
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [25] Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma
    Jena, Rabindra Kumar
    Swain, Trupti Rekha
    Kansurkar, Sandeep Sadashivrao
    Swain, Manorama
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (05) : 881 - 884
  • [26] Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis
    Baz, Rachid
    Patel, Mehul
    Finley-Oliver, Elizabeth
    Lebovic, Daniel
    Hussein, Mohamad A.
    Miller, Kena C.
    Wood, Margaret
    Sher, Taimur
    Lee, Kelvin
    Chanan-Khan, Asher A.
    LEUKEMIA & LYMPHOMA, 2010, 51 (06) : 1015 - 1019
  • [27] Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    Rajkumar, SV
    Hayman, SR
    Lacy, MQ
    Dispenzieri, A
    Geyer, SM
    Kabat, B
    Zeldenrust, SR
    Kumar, S
    Greipp, PR
    Fonseca, R
    Lust, JA
    Russell, SJ
    Kyle, RA
    Witzig, TE
    Gertz, MA
    BLOOD, 2005, 106 (13) : 4050 - 4053
  • [28] Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma
    Gay, Francesca
    Rajkumar, S. Vincent
    Falco, Patrizia
    Kumar, Shaji
    Dispenzieri, Angela
    Petrucci, Maria Teresa
    Gertz, Morie A.
    Boccadoro, Mario
    Stewart, A. Keith
    Palumbo, Antonio
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (03) : 200 - 208
  • [29] Factors associated with dose adjustment for the bortezomib, lenalidomide, dexamethasone regimen among patients with newly diagnosed multiple myeloma.
    Ran, Tao
    Medhekar, Rohan
    Fu, Alex Z.
    Patel, Sharmila
    Kaila, Shuchita
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Daratumumab plus Lenalidomide/ dexamethasone in transplant-neligible patients with newly diagnosed multiple myeloma: MAIA update
    Basu, Supratik
    Kumar, Shaji K.
    Moreau, Philippe
    Bahlis, Nizar
    Facon, Thierry
    Plesner, Torben
    Orlowski, Robert Z.
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Raje, Noopur
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Pei, Huiling
    Krevvata, Maria
    Borgsten, Fredrik
    Usmani, Saad Z.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 17 - 18
12345